Walder Wyss with ExcellGene and Magellan on sale to Archimed
Walder Wyss advised ExcellGene and Magellan Biologics & Consulting Global, on the sale of a majority stake to private equity healthcare specialist Archimed.
The deal sets to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins.
The Walder Wyss team
Partner Luc Defferrard (corporate/M&A, pictured) led the Walder Wyss team on the matter, working alongside senior associate Caroline Sauthier (corporate/M&A), associate Matteo Berti (corporate/M&A), counsel Laura Luongo (employment), partner Fabienne Limacher (tax), and associate Daniela Hottiger (tax).
